AIMC Topic: Cytokine Release Syndrome

Clear Filters Showing 1 to 4 of 4 articles

Classification of patients with relapsed/refractory large B-cell lymphoma who do not develop early CRS/NE toxicity using ZUMA clinical trial data.

Journal for immunotherapy of cancer
BACKGROUND: We aimed to develop an actionable and feasible prospective clinical model to estimate toxicity risk to assist chimeric antigen receptor (CAR) T-cell therapy providers with the management of patients with relapsed and/or refractory large B...

PrCRS: a prediction model of severe CRS in CAR-T therapy based on transfer learning.

BMC bioinformatics
BACKGROUND: CAR-T cell therapy represents a novel approach for the treatment of hematologic malignancies and solid tumors. However, its implementation is accompanied by the emergence of potentially life-threatening adverse events known as cytokine re...

Challenging molecular dogmas in human sepsis using mathematical reasoning.

EBioMedicine
Sepsis is defined as a dysregulated host-response to infection, across all ages and pathogens. What defines a dysregulated state remains intensively researched but incompletely understood. Here, we dissect the meaning of this definition and its impor...

Machine learning-based cytokine microarray digital immunoassay analysis.

Biosensors & bioelectronics
Serial measurement of a large panel of protein biomarkers near the bedside could provide a promising pathway to transform the critical care of acutely ill patients. However, attaining the combination of high sensitivity and multiplexity with a short ...